Skip to content

US · RCUS · BIOTECHNOLOGY

Arcus Biosciences, Inc. (RCUS) intrinsic value and stock valuation

$15.62as of 2026-11-21 · Mkt cap 3.6B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Arcus Biosciences, Inc. DCF and intrinsic value

InvestorsCraft values RCUS with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from RCUS’s statements →

Arcus Biosciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Hayward, CA 94545 arcusbio.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$247M+25.9% 5y CAGRd
20162025
Net income
-$-353M
20162025
Free cash flow
-$-484M
20162025
Total equity
$631M+4.7% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$247M$258M$117M$112M$383M
Operating income-$-386M-$-330M-$-340M-$-280M$54M
Net income-$-353M-$-283M-$-307M-$-267M$53M
EPSd-$-3.29M-$-3.14M-$-4.15M-$-3.71M$716.5K
Operating cash flow-$-482M-$-170M-$-306M$438M-$-256.17M
Capital expenditure-$-2M-$-6M-$-24M-$-6M-$-26.08M
Free cash flow-$-484M-$-176M-$-330M$432M-$-282.25M
Total assets$1.14B$1.15B$1.1B$1.35B$1.59B
Total debt$112M$60M$11M$120M$122M
Net debt-$-110M-$-90M-$-116M-$-86M-$-25.93M
Total equity$631M$485M$462M$657M$841.5M
Cash and short-term investments$981M$978M$759M$1.01B$499.3M
Income statement
20252024202320222021
Revenue$247M$258M$117M$112M$383M
Cost of revenue$10M$0.00$0.00$0.00$0.00
Gross profit$237M$258M$117M$112M$383M
Research and development expenses$523M$448M$340M$288M$257M
Selling, general and administrative expenses$110M$120M$117M$104M$72M
Other expenses-$-10M$20M$0.00$0.00$0.00
Operating expenses$623M$588M$457M$392M$329M
Cost and expenses$633M$588M$457M$392M$329M
Interest income$41M$52M$41M$16M$1M
Interest expense$8M$4M$2M$2M$0.00
Depreciation and amortization$10M$10M$8M$6M$4M
Ebitda-$-335M-$-269M-$-291M-$-258M$59M
Operating income-$-386M-$-330M-$-340M-$-280M$54M
Total other income/expenses, net$33M$47M$39M$14M$1M
Income before tax-$-353M-$-283M-$-301M-$-266M$55M
Income tax expense$0.00$1M$6M$1M$2M
Net income-$-353M-$-283M-$-307M-$-267M$53M
Weighted average shares outstanding$107.4M$90.1M$74M$72M$69.4M
Weighted average diluted shares outstanding$107.4M$90.1M$74M$72M$74M
Balance sheet
20252024202320222021
Cash and short-term investments$981M$978M$759M$1.01B$499.3M
Net receivables$16M$25M$42M$43M$746.8M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$1.01B$1.02B$831M$1.07B$1.26B
Property, plant and equipment, net$40M$47M$51M$135M$137.4M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$29M$14M$107M$134M$185M
Total non-current assets$132M$134M$264M$279M$330.2M
Total assets$1.14B$1.15B$1.1B$1.35B$1.59B
Accounts payable$42M$18M$17M$20M$10.3M
Short-term debt$13M$12M$11M$3M$5.1M
Deferred revenue$35M$85M$91M$97M$102M
Total current liabilities$231M$226M$184M$193M$166.1M
Long-term debt$99M$48M$0.00$117M$116.9M
Deferred revenue, non-current$43M$234M$307M$355M$462.2M
Total non-current liabilities$277M$439M$449M$495M$584.4M
Capital lease obligations$13M$12M$11M$117M$116.9M
Total liabilities$508M$665M$633M$688M$750.5M
Common stock$2.12B$1.62B$1.31B$1.21B$10K
Retained earnings-$-1.49B-$-1.13B-$-849M-$-542M-$-275.35M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00-$-7M-$-1.26M
Total equity$631M$485M$462M$657M$841.5M
Total investments$788M$842M$739M$937M$536.4M
Total debt$112M$60M$11M$120M$122M
Net debt-$-110M-$-90M-$-116M-$-86M-$-25.93M
Cash flow statement
20252024202320222021
Net income-$-353M-$-283M-$-307M-$-267M$52.8M
Depreciation and amortization$10M$10M$8M$14M$3.84M
Stock-based compensation$60M$76M$73M$65M$55M
Change in working capital-$-194M$22M-$-71M$623M-$-375.62M
Accounts receivable$9M$28M$15M$704M-$-17.05M
Inventory$0.00$0.00$0.00$0.00$14.1M
Accounts payable$24M$3M-$-1M$8M-$-4.77M
Net cash provided by operating activities-$-482M-$-170M-$-306M$438M-$-256.17M
Investments in property, plant and equipment-$-2M-$-6M-$-24M-$-6M-$-26.08M
Acquisitions, net$0.00$0.00$0.00$0.00-$-22M
Net cash used for investing activities$66M-$-84M$194M-$-413M-$-3.87M
Common stock issued$439M$228M$25M$23M$220M
Common stock repurchased$0.00$0.00$0.00$0.00-$-10K
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$488M$277M$33M$33M$237.3M
Net change in cash$72M$23M-$-79M$58.1M-$-22.7M
Cash at end of period$225M$153M$130M$206M$150.9M
Operating cash flow-$-482M-$-170M-$-306M$438M-$-256.17M
Capital expenditure-$-2M-$-6M-$-24M-$-6M-$-26.08M
Free cash flow-$-484M-$-176M-$-330M$432M-$-282.25M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Arcus Biosciences, Inc.

        Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

        CEO
        Terry J. Rosen
        Employees
        601
        Beta
        0.80

        Explore

        Frequently asked questions

        What is the intrinsic value of Arcus Biosciences, Inc. (RCUS)?

        Arcus Biosciences, Inc. (RCUS) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is RCUS undervalued?

        RCUS trades at a price of $15.62 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.